Metabolic and liver care | New York

Wegovy for MASH evaluation and coordination

Wegovy injection is approved for adults with noncirrhotic MASH and F2–F3 fibrosis under accelerated approval. The MASH indication belongs to the injection and should not be applied to oral Wegovy.

Wegovy for MASH

Wegovy injection is approved for adults with noncirrhotic MASH and F2–F3 fibrosis under accelerated approval. The MASH indication belongs to the injection and should not be applied to oral Wegovy.

How Wegovy for MASH works

Semaglutide activates GLP-1 receptors and has metabolic effects. MASH eligibility depends on liver disease and fibrosis, not only on weight or liver fat. Accelerated approval means the initial endpoint supported approval while confirmatory benefit remains required.

Eligibility: Wegovy for MASH

Adults need documented noncirrhotic MASH with moderate-to-advanced fibrosis consistent with F2–F3. Simple steatosis, a normal ALT, or weight loss does not establish diagnosis, resolution, or eligibility.

What to expect: Wegovy for MASH

Review liver and fibrosis records, metabolic conditions, previous treatment, and GLP-1 safety. Coordinate with hepatology when necessary. Choose the injection regimen for the MASH indication, then plan nutrition, symptoms, liver follow-up, and medication continuity.

Preparing for your appointment

Bring liver imaging, fibrosis assessments, biopsy if available, liver tests, and GI notes. Include all medicines, supplements, and pregnancy plans.

Risks and when to seek help

Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Pregnancy wording for the MASH indication requires an individualized benefit-risk review. Do not transfer weight-loss pregnancy advice into a claim that MASH treatment is automatically safe during pregnancy.

Follow-up and treatment review

Continue liver and metabolic follow-up even if weight or enzymes improve. Review symptoms and tolerability with the treating team. Treatment combinations and dose changes require clinical review.

Appointments, costs and coverage

Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.

Questions about your care

What is MASH?

MASH means metabolic dysfunction-associated steatohepatitis: liver fat with inflammation and injury. Fibrosis is scarring and is staged separately. A fatty-liver scan alone does not establish MASH with F2–F3 fibrosis or eligibility for a labeled MASH medicine.

Who is Wegovy approved to treat for MASH?

Is oral Wegovy approved for MASH?

No. The Wegovy MASH indication belongs to the injection. Wegovy tablets have adult weight and qualifying cardiovascular indications, not the injection’s MASH indication. Product choice must follow the exact formulation’s label.

Is Wegovy approved for simple fatty liver?

No. Liver fat on imaging does not by itself establish noncirrhotic MASH with F2–F3 fibrosis. The clinician reviews diagnosis, severity, and other causes before deciding whether Rezdiffra or Wegovy injection’s MASH indication fits.

What does accelerated approval mean?

Accelerated approval uses an endpoint reasonably likely to predict clinical benefit. The Rezdiffra and Wegovy MASH indications require confirmatory benefit under their labels. It is an FDA approval pathway, but it should not be described as proof that all long-term liver outcomes are established.

Can Nao Medical diagnose and manage all liver disease?

No single outpatient service should be assumed to manage every liver disease. Confirm the available evaluation and referral arrangements before booking. Cirrhosis, uncertain fibrosis, other causes of liver injury, and urgent symptoms may require hepatology or hospital care.

What records are needed?

Bring liver imaging, fibrosis assessments, biopsy if available, liver tests, and GI notes. Include all medicines, supplements, and pregnancy plans.

Medical sources

Confirm the labeled liver condition

Document MASH

The clinician should review how the diagnosis was established and whether another liver disease has been excluded.

Document fibrosis stage

The current label is for moderate-to-advanced F2 to F3 fibrosis in adults without cirrhosis.

Review liver status

Possible cirrhosis, decompensation, significant alcohol exposure, viral hepatitis, or another complex condition needs appropriate hepatology evaluation.

Coordinate the complete plan

Liver-specialist input

Confirm who owns staging, surveillance, treatment monitoring, and management of other liver risks.

Metabolic treatment

Address weight, diabetes, blood pressure, cholesterol, nutrition, activity, and medicines that affect liver or metabolic health.

Wegovy safety

Review contraindications, gastrointestinal and gallbladder concerns, pancreatitis symptoms, kidney risk from dehydration, diabetes eye history, pregnancy, and procedure plans.

Understand accelerated approval

Current evidence boundary

The label states that continued approval may depend on verification and description of clinical benefit in a confirmatory trial.

Injection only

The recommended MASH maintenance regimen is Wegovy injection. The tablet does not carry the MASH indication.

Discussing your care

The clinical and operational review may instead lead to more diagnostic work, hepatology care, another treatment, or no medication change.

Evaluation locations across New York